Use of erythrocytapheresis in the treatment of patients with sickle cell anemia.
We performed exchange transfusions, utilizing the technique of automated erythrocytapheresis, for the treatment of patients with sickle cell anemia. In an attempt to determine guidelines for the use of erythrocytapheresis, we studied the use of this procedure in three distinct clinical situations in nine patients with sickle cell disease. Patients with dangerous complications of sickle cell disease such as acute respiratory distress and priapism responded well to erythrocytapheresis, showing marked improvement within 24-48 hours. Patients with prolonged painful vasoocclusive crises showed only variable improvement after erythrocytapheresis therapy, insufficient to justify exposing the patient to the risks of the procedure. Patients treated to decrease the frequency of painful crises demonstrated no prolongation in symptom-free intervals between crises. Therefore, erythrocytapheresis has its main value in the management of acute, dangerous complications of sickle cell disease.
D000328:Adult; D000755:Anemia, Sickle Cell / Q000628:therapy*; D002648:Child; D003365:Costs and Cost Analysis; D005078:Exchange Transfusion, Whole Blood / Q000009:adverse effects / Q000191:economics / Q000295:instrumentation* / Q000592:standards; D006801:Humans; D008297:Male; D011317:Priapism / Q000628:therapy; D012128:Respiratory Distress Syndrome / Q000628:therapy